Find a Research Lab

Enter a research interest, principal investigator or keyword

Displaying 11 to 12 of 12 results for gastrointestinal

Show: 10 · 20 · 50

  1. 1
  2. 2
  • The Hackam Lab for Pediatric Surgical, Translational and Regenerative Medicine

    David Hackam’s laboratory focuses on necrotizing enterocolitis (NEC), a devastating disease of premature infants and the leading cause of death and disability from gastrointestinal disease in newborns.

    The disease strikes acutely and without warning, causing sudden death of the small and large intestines. In severe cases, tiny patients with the disease are either dying or dead from overwhelming sepsis within 24 hours. Surgical treatment to remove most of the affected gut results in lifelong short gut (short bowel) syndrome.

    The Hackam Lab has identified a critical role for the innate immune receptor toll-like receptor 4 (TLR4) in the pathogenesis of necrotizing enterocolitis. The lab has shown that TLR4 regulates the development of the disease by tipping the balance between injury and repair in the stressed intestine of the premature infant. Developing an Artificial Intestine A key goal is to create, in the laboratory, new intestines made from patients’ own cells, which can then ...be implanted into the patient to restore normal digestive function. This innovative design could transform child development and quality of life in necrotizing enterocolitis survivors without the risks of conventional donor transplant. view more

    Research Areas: necrotizing enterocolitis, gut inflammation, stem cell biology, premature infants, TLR4

    Lab Website

    Principal Investigator

    David Hackam, M.D., Ph.D.

    Department

    Pediatrics
    Surgery

  • Zsuzsanna McMahan Lab

    The Zsuzsanna McMahan Lab conducts translational research that seeks to identify the novel antigens in scleroderma and to define the target tissue in this disease. We are conducting two active clinical research trials, including one that studies skin biopsy specimens as biomarkers of scleroderma and the response to mycophenolate mofetil (MMF or Cellcept). The other study is a gastrointestinal involvement registry that follows patients who are experiencing GERD, small bowel bacterial overgrowth, constipation, fecal incontinence and gastroparesis to see if there is improvement in symptoms after a change in treatment is implemented.

    Research Areas: gastrointestinal system, rheumatology, biomarkers, scleroderma, antigens, mycophenolate mofetil

    Lab Website

    Principal Investigator

    Zsuzsanna McMahan, M.D., M.H.S.

    Department

    Medicine

  1. 1
  2. 2